Childhood Cancer Data Initiative (CCDI): NCI-COG Pediatric MATCH Precision Medicine Clinical Trial

Target and Agent Prioritization for the Children’s Oncology Group—National Cancer Institute Pediatric MATCH Trial

Carl E. Allen, Theodore W. Laetsch, R. Mody, et al.. (2017). Journal Of The National Cancer Institute. Cited 97 times. https://doi.org/10.1093/jnci/djw274

Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute–Children's Oncology Group Pediatric MATCH Trial

D. W. Parsons, K. Janeway, D. Patton, et al.. (2022). Journal of Clinical Oncology. Cited 79 times. https://doi.org/10.1200/JCO.21.02838

Tazemetostat for Tumors Harboring SMARCB1/SMARCA4 or EZH2 Alterations: Results from NCI-COG Pediatric MATCH APEC1621C.

S. Chi, Joanna S. Yi, P. Williams, et al.. (2023). Journal of the National Cancer Institute. Cited 62 times. https://doi.org/10.1093/jnci/djad085

Phase II Study of Selumetinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Genetic Alterations: Arm E of the NCI-COG Pediatric MATCH Trial

O. Eckstein, C. Allen, P. Williams, et al.. (2022). Journal of Clinical Oncology. Cited 36 times. https://doi.org/10.1200/JCO.21.02840

Olaparib for childhood tumors harboring defects in DNA damage repair genes: arm H of the NCI-COG Pediatric MATCH trial

J. G. Glade Bender, Kerice Pinkney, P. M. Williams, et al.. (2024). The Oncologist. Cited 6 times. https://doi.org/10.1093/oncolo/oyae096

Phase II study of vemurafenib in children and young adults with tumors harboring BRAF V600 mutations: NCI-COG pediatric MATCH trial (APEC1621) Arm G

Marie V Nelson, A. Kim, P. Williams, et al.. (2024). The Oncologist. Cited 5 times. https://doi.org/10.1093/oncolo/oyae119

Children Successfully MATCHed to Therapies.

(2019). Cancer discovery. Cited 5 times. https://doi.org/10.1158/2159-8290.CD-NB2019-059